Details for Patent: 9,060,939
✉ Email this page to a colleague
Which drugs does patent 9,060,939 protect, and when does it expire?
Patent 9,060,939 protects LYSTEDA and is included in one NDA.
This patent has eight patent family members in two countries.
Summary for Patent: 9,060,939
Title: | Tranexamic acid formulations |
Abstract: | Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. |
Inventor(s): | Moore; Keith A. (Loveland, OH), Heasley; Ralph A. (Webster Grove, MO), Greiwe; Jeffrey S. (Ft. Thomas, KY), Facemire; John W. (Douglasville, GA), Modest; Jason D. (Minneapolis, MN) |
Assignee: | Ferring B.V. (Hoofddorp, NL) |
Application Number: | 13/230,902 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,060,939 |
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; Use; | More… ↓ |
Drugs Protected by US Patent 9,060,939
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amring Pharms | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,060,939
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Japan | 2008508275 | ⤷ Subscribe | |||
Japan | 2008508276 | ⤷ Subscribe | |||
Japan | 2011168596 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |